Chongqing Lummy Pharmaceutical (300006) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Chongqing Lummy Pharmaceutical (300006) has a cash flow conversion efficiency ratio of -0.008x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-14.90 Million ≈ $-2.18 Million USD) by net assets (CN¥1.85 Billion ≈ $271.01 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Chongqing Lummy Pharmaceutical defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Chongqing Lummy Pharmaceutical - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Chongqing Lummy Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Chongqing Lummy Pharmaceutical Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chongqing Lummy Pharmaceutical ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangdong Senssun Weighing Apparatus Group Ltd
SHE:002870
|
0.049x |
|
Guanghui Logistics Co Ltd
SHG:600603
|
0.005x |
|
Compass Diversified Holdings
NYSE:CODI
|
0.045x |
|
Nuh Cimento Sanayi AS
IS:NUHCM
|
0.028x |
|
Costar Group Co Ltd
SHE:002189
|
0.005x |
|
Shenzhen TXD Technology Co Ltd
SHE:002845
|
-0.017x |
|
Inly Media Co Ltd
SHG:603598
|
-1.087x |
|
Lloyds Banking Group PLC
LSE:LLOY
|
0.141x |
Annual Cash Flow Conversion Efficiency for Chongqing Lummy Pharmaceutical (2006–2024)
The table below shows the annual cash flow conversion efficiency of Chongqing Lummy Pharmaceutical from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see Chongqing Lummy Pharmaceutical stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.88 Billion ≈ $275.59 Million |
CN¥185.03 Million ≈ $27.08 Million |
0.098x | +155.72% |
| 2023-12-31 | CN¥2.12 Billion ≈ $310.54 Million |
CN¥81.53 Million ≈ $11.93 Million |
0.038x | +46.92% |
| 2022-12-31 | CN¥2.18 Billion ≈ $319.73 Million |
CN¥57.13 Million ≈ $8.36 Million |
0.026x | -46.58% |
| 2021-12-31 | CN¥2.21 Billion ≈ $323.70 Million |
CN¥108.28 Million ≈ $15.84 Million |
0.049x | -73.15% |
| 2020-12-31 | CN¥1.23 Billion ≈ $180.22 Million |
CN¥224.54 Million ≈ $32.86 Million |
0.182x | +30.35% |
| 2019-12-31 | CN¥1.65 Billion ≈ $241.99 Million |
CN¥231.30 Million ≈ $33.85 Million |
0.140x | +6.75% |
| 2018-12-31 | CN¥1.72 Billion ≈ $252.28 Million |
CN¥225.89 Million ≈ $33.05 Million |
0.131x | +267.72% |
| 2017-12-31 | CN¥1.72 Billion ≈ $252.11 Million |
CN¥61.39 Million ≈ $8.98 Million |
0.036x | -52.53% |
| 2016-12-31 | CN¥1.67 Billion ≈ $245.00 Million |
CN¥125.66 Million ≈ $18.39 Million |
0.075x | +599.18% |
| 2015-12-31 | CN¥1.69 Billion ≈ $247.28 Million |
CN¥-25.41 Million ≈ $-3.72 Million |
-0.015x | +69.04% |
| 2014-12-31 | CN¥1.02 Billion ≈ $148.81 Million |
CN¥-49.38 Million ≈ $-7.23 Million |
-0.049x | -173.18% |
| 2013-12-31 | CN¥1.13 Billion ≈ $164.73 Million |
CN¥74.70 Million ≈ $10.93 Million |
0.066x | +159.29% |
| 2012-12-31 | CN¥710.51 Million ≈ $103.97 Million |
CN¥18.18 Million ≈ $2.66 Million |
0.026x | +42.56% |
| 2011-12-31 | CN¥660.17 Million ≈ $96.60 Million |
CN¥11.85 Million ≈ $1.73 Million |
0.018x | -73.23% |
| 2010-12-31 | CN¥561.59 Million ≈ $82.18 Million |
CN¥37.66 Million ≈ $5.51 Million |
0.067x | -5.73% |
| 2009-12-31 | CN¥525.08 Million ≈ $76.84 Million |
CN¥37.35 Million ≈ $5.47 Million |
0.071x | -43.18% |
| 2008-12-31 | CN¥137.79 Million ≈ $20.16 Million |
CN¥17.25 Million ≈ $2.52 Million |
0.125x | -37.70% |
| 2007-12-31 | CN¥107.91 Million ≈ $15.79 Million |
CN¥21.68 Million ≈ $3.17 Million |
0.201x | +66.59% |
| 2006-12-31 | CN¥64.39 Million ≈ $9.42 Million |
CN¥7.77 Million ≈ $1.14 Million |
0.121x | -- |
About Chongqing Lummy Pharmaceutical
Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It provides anti-tumor, anti-inflammatory, antibacterial, digestive, anti-virus, blood system, cardiovascular system, acid-base balance nutritional medicine, endocrine system drugs, tumor adjuvant medication, antifungal, and opioid receptor antagonists. Chon… Read more